Full Press Release Details
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD)
PRIMA BIOMED TO MAINTAIN
SYDNEY, AUSTRALIA Prima BioMed Ltd (NASDAQ: PBMD; ASX: PRR) ( Prima , the Company ), announces that, further
to the announcement made on 29 December 2014, it has received a notice, dated 3 June 2015 from the Listing Qualifications Department of The NASDAQ Stock Market indicating that, for the 10 consecutive business days from 19 May 2015 to
2 June 2015, the closing bid price of the Company s American Depositary Shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5450(a)(1) ( the Minimum Bid Price Rule )
and the Company s shares will remain listed on The NASDAQ Global Market.
Prima BioMed is a globally active biotechnology company that is striving to become a leader in the development of immunotherapeutic products for the treatment
of cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.
Prima s original product, called CVac, is an ex vivo dendritic cell priming therapy that in May 2015 yielded favourable Phase II data in
second remission ovarian cancer patients. Prima is currently seeking partners for further development of this therapy. Prima s current lead product is IMP321, based on the LAG-3 immune control mechanism which plays a vital role in the
regulation of the T cell immune response. IMP321, which is soluble LAG-3, is a T cell immunostimulatory factor for cancer chemoimmunotherapy which has completed early Phase II trials. A number of additional LAG-3 products including
antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.
Prima BioMed is listed on the
Australian stock exchange and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au.
For further information
Roberts, Global Head of Investor Relations
+61 (0) 447 247 909; stuart.roberts@primabiomed.com.au
Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 8569 1880
www.primabiomed.com.au ABN: 90 009 237 889
Adam Holdsworth, ProActive Capital
Australia Investor/Media:
Mr Matthew Gregorowski, Citadel Communications
534 755; mgregorowski@citadelpr.com.au
Europe Investor/Media:
Mr. Axel M hlhaus, edicto GmbH
905505-52; amuehlhaus@edicto.de
Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284
www.primabiomed.com.au ABN: 90 009 237 889